{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:28:03Z","timestamp":1788449283691,"version":"build-2803163510"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>There is increasing evidence suggesting that Epstein-Barr virus infection is a causative factor of multiple sclerosis (MS). Epstein-Barr virus (EBV) is a human herpesvirus, Human Gammaherpesvirus 4. EBV infection shows two peaks: firstly, during early childhood and, secondly during the teenage years. Approximately, 90\u201395% of adults have been infected with EBV and for many this will have been a subclinical event. EBV infection can be associated with significant morbidity and mortality; for example, primary infection in older children or adults is the leading cause of infectious mononucleosis (IM). A disrupted immune response either iatrogenically induced or through genetic defects can result in lymphoproliferative disease. Finally, EBV is oncogenic and is associated with several malignancies. For these reasons, vaccination to prevent the damaging aspects of EBV infection is an attractive intervention. No EBV vaccines have been licensed and the prophylactic vaccine furthest along in clinical trials contains the major virus glycoprotein gp350. In a phase 2 study, the vaccine reduced the rate of IM by 78% but did not prevent EBV infection. An EBV vaccine to prevent IM in adolescence or young adulthood is the most likely population-based vaccine strategy to be tested and adopted. National registry studies will need to be done to track the incidence of MS in EBV-vaccinated and unvaccinated people to see an effect of the vaccine on MS. Assessment of vaccine efficacy with MS being a delayed consequence of EBV infection with the average age of onset being approximately 30 years of age represents multiple challenges.<\/jats:p>","DOI":"10.3389\/fneur.2022.887794","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T06:51:26Z","timestamp":1656053486000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["The Potential for EBV Vaccines to Prevent Multiple Sclerosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Peter A.","family":"Maple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ascherio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Shannon-Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Tanasescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Gran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1007\/s00705-021-05156-1","article-title":"Changes to virus taxonomy and to the international code of virus classification and nomenclature ratified by the international committee on taxonomy of viruses","volume":"166","author":"Walker","year":"2021","journal-title":"Arch Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from burkitt's lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/310207a0","article-title":"DNA sequence and expression of the B95-8 Epstein-Barr virus genome","volume":"310","author":"Baer","year":"1984","journal-title":"Nature."},{"key":"B4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.virol.2006.01.015","article-title":"The genome of Epstein-Barr virus type 2 strain AG876","volume":"350","author":"Dolan","year":"2006","journal-title":"Virology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat Rev Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41390-019-0591-5","article-title":"The promise of a prophylactic Epstein-Barr virus vaccine","volume":"87","author":"Balfour","year":"2020","journal-title":"Pediatr Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0952-7915(99)80062-4","article-title":"The biology of Epstein-Barr virus: lessons learned from the virus and the host","volume":"11","author":"Cohen","year":"1999","journal-title":"Curr Opin Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.3390\/v13122344","article-title":"Molecular basis of epstein-barr virus latency establishment and lytic reactivation","volume":"13","author":"Murata","year":"2021","journal-title":"Viruses."},{"key":"B9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/mp.53.5.238","article-title":"The expression and function of Epstein-Barr virus encoded latent genes","volume":"53","author":"Young","year":"2000","journal-title":"Mol Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e61110","DOI":"10.1371\/journal.pone.0061110","article-title":"Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis","volume":"8","author":"Almohmeed","year":"2013","journal-title":"PLoS ONE."},{"key":"B11","doi-asserted-by":"publisher","first-page":"587380","DOI":"10.3389\/fimmu.2020.587380","article-title":"Epstein-Barr virus and systemic autoimmune diseases","volume":"11","author":"Houen","year":"2021","journal-title":"Front Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr virus infection","volume":"102","author":"Dunmire","year":"2018","journal-title":"J Clin Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1038\/cti.2015.1","article-title":"Infectious mononucleosis","volume":"4","author":"Balfour","year":"2015","journal-title":"Clin Transl Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1128\/CMR.00044-10","article-title":"Progress and problems in understanding and managing primary Epstein-Barr virus infections","volume":"24","author":"Odumade","year":"2011","journal-title":"Clin Microbiol Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/QCO.0000000000000787","article-title":"Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes","volume":"34","author":"Lindsay","year":"2021","journal-title":"Curr Opin Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1365-2141.2010.08442.x","article-title":"X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma","volume":"152","author":"Rezaei","year":"2011","journal-title":"Br J Haematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr Virus and Cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu Rev Pathol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1038\/cti.2016.28","article-title":"Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study","volume":"5","author":"Johnson","year":"2016","journal-title":"Clin Transl Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1086\/510854","article-title":"A study of risk factors for acquisition of Epstein-Barr virus and its subtypes","volume":"195","author":"Higgins","year":"2007","journal-title":"J Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/femsre\/fuz023","article-title":"Epithelial cell infection by Epstein-Barr virus","volume":"43","author":"Chen","year":"2019","journal-title":"FEMS Microbiol Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coviro.2021.11.013","article-title":"Epigenetic control of the Epstein-Barr lifecycle","volume":"52","author":"Guo","year":"2021","journal-title":"Curr Opin Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/jmv.10132","article-title":"Sero-epidemiological patterns of Epstein-Barr and herpes simplex (HSV-1 and HSV-2) viruses in England and Wales","volume":"67","author":"Morris","year":"2002","journal-title":"J Med Virol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e64921","DOI":"10.1371\/journal.pone.0064921","article-title":"Seroprevalence of Epstein-Barr virus infection in U","volume":"8","author":"Dowd","year":"2013","journal-title":"PLoS ONE."},{"key":"B24","doi-asserted-by":"publisher","first-page":"010404","DOI":"10.7189\/jogh.10.010404","article-title":"Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature","volume":"10","author":"Winter","year":"2020","journal-title":"J Glob Health."},{"key":"B25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science."},{"key":"B27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-pathol-052920-040318","article-title":"The immune response in multiple sclerosis","volume":"17","author":"Murua","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1906","DOI":"10.1212\/WNL.0000000000012782","article-title":"Clinical correlation of multiple sclerosis immunopathologic subtypes","volume":"97","author":"Tobin","year":"2021","journal-title":"Neurology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00281-021-00907-3","article-title":"Genetics and functional genomics of multiple sclerosis","volume":"44","author":"Kim","year":"2022","journal-title":"Semin Immunopathol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/2055217317690184","article-title":"An essential role of virus-infected B cells in the marmoset experimental autoimmune encephalomyelitis model","author":"T Hart","year":"2017","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/eji.201646485","article-title":"Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis","volume":"46","author":"Martin","year":"2016","journal-title":"Eur J Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Machado-Santos","year":"2018","journal-title":"Brain."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple Sclerosis Pathology","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.tig.2017.09.004","article-title":"The genetics of multiple sclerosis: from 0 to 200 in 50 years","volume":"33","author":"Baranzini","year":"2017","journal-title":"Trends Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"103594","DOI":"10.1016\/j.ebiom.2021.103594","article-title":"Kissing genetic MS risk loci to life","volume":"72","author":"Munz","year":"2021","journal-title":"EBioMed."},{"key":"B36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/jnnp-2020-325676","article-title":"DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies","volume":"92","author":"Hedstrom","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e41678","DOI":"10.1371\/journal.pone.0041678","article-title":"Vitamin D responsive elements within the HLA-DRB1 promoter region in Sardinian multiple sclerosis associated alleles","volume":"7","author":"Cocco","year":"2012","journal-title":"PLoS ONE."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0172415","DOI":"10.1371\/journal.pone.0172415","article-title":"The association between human endogenous retroviruses and multiple sclerosis: a systematic review and meta-analysis","volume":"12","author":"Morandi","year":"2017","journal-title":"PLoS ONE."},{"key":"B39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1080\/14737175.2021.1978843","article-title":"Role of environmental factors in multiple sclerosis","volume":"21","author":"Zarghami","year":"2021","journal-title":"Expert Rev Neurother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/ntr\/ntx084","article-title":"Smoking cessation and the reduction of disability progression in multiple sclerosis: a cohort study","volume":"20","author":"Tanasescu","year":"2018","journal-title":"Nicotine Tob Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1111\/ene.13719","article-title":"Response to 'Seasonal variation of vitamin D and Epstein-Barr virus antibody in multiple sclerosis patients', a comment letter regarding 'Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients'","volume":"25","author":"Wergeland","year":"2018","journal-title":"Eur J Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.20820","article-title":"Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis","volume":"59","author":"Thacker","year":"2006","journal-title":"Ann Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ana.21117","article-title":"Environmental risk factors for multiple sclerosis. Part I: the role of infection","volume":"61","author":"Ascherio","year":"2007","journal-title":"Ann Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/archneur.64.1.72","article-title":"Multiple sclerosis after infectious mononucleosis","volume":"64","author":"Nielsen","year":"2007","journal-title":"Arch Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMra020100","article-title":"The effect of infections on susceptibility to autoimmune and allergic diseases","volume":"347","author":"Bach","year":"2002","journal-title":"N Engl J Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00001648-200003000-00023","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"11","author":"Ascherio","year":"2000","journal-title":"Epidemiology."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1001\/jama.291.15.1875","article-title":"Epstein-Barr virus in pediatric multiple sclerosis","volume":"291","author":"Alotaibi","year":"2004","journal-title":"JAMA."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1212\/01.wnl.0000247665.94088.8d","article-title":"High seroprevalence of Epstein-Barr virus in children with multiple sclerosis","volume":"67","author":"Pohl","year":"2006","journal-title":"Neurology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","article-title":"Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study","volume":"286","author":"Ascherio","year":"2001","journal-title":"JAMA."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1212\/01.WNL.0000130496.51156.D7","article-title":"An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study","volume":"62","author":"Sundstrom","year":"2004","journal-title":"Neurology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1001\/jama.293.20.2496","article-title":"Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis","volume":"293","author":"Levin","year":"2005","journal-title":"JAMA."},{"key":"B53","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1001\/archneur.63.6.noc50328","article-title":"Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up","volume":"63","author":"Delorenze","year":"2006","journal-title":"Arch Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/1352458511408991","article-title":"Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel","volume":"17","author":"Munger","year":"2011","journal-title":"Mult Scler."},{"key":"B55","doi-asserted-by":"publisher","first-page":"aaa0698","DOI":"10.1126\/science.aaa0698","article-title":"Comprehensive serological profiling of human populations using a synthetic human virome","volume":"348","author":"Xu","year":"2015","journal-title":"Science."},{"key":"B56","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.immuni.2022.02.008","article-title":"How does Epstein-Barr virus trigger MS?","volume":"55","author":"Kuchroo","year":"2022","journal-title":"Immunity."},{"key":"B57","doi-asserted-by":"publisher","first-page":"103636","DOI":"10.1016\/j.msard.2022.103636","article-title":"Is EBV the cause of multiple sclerosis?","volume":"58","author":"Giovannoni","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1128\/JVI.01409-07","article-title":"Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis","volume":"82","author":"Elliott","year":"2008","journal-title":"J Virol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in b cells and epithelial cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030285","article-title":"Immunization with Epstein-Barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge","author":"Cui","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020169","article-title":"A pentavalent epstein-barr virus-like particle vaccine elicits high titers of neutralizing antibodies against Epstein-Barr virus infection in immunized rabbits","author":"Escalante","year":"2020","journal-title":"Vaccines (Basel)."},{"key":"B65","doi-asserted-by":"publisher","first-page":"13105","DOI":"10.1128\/JVI.05598-11","article-title":"A virus-like particle-based Epstein-Barr virus vaccine","volume":"85","author":"Ruiss","year":"2011","journal-title":"J Virol."},{"key":"B66","unstructured":"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults"},{"key":"B67","unstructured":"Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection [Online]"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e1005549","DOI":"10.1371\/journal.ppat.1005549","article-title":"Early T cell recognition of B cells following epstein-barr virus infection: identifying potential targets for prophylactic vaccination","volume":"12","author":"Brooks","year":"2016","journal-title":"PLoS Pathog."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e1010137","DOI":"10.1371\/journal.ppat.1010137","article-title":"Cytotoxic CD4+ T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors","volume":"17","author":"Dowell","year":"2021","journal-title":"PLoS Pathog."},{"key":"B70","first-page":"6952","article-title":"Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e976507","DOI":"10.4161\/23723556.2014.976507","article-title":"Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"4","author":"Li","year":"2015","journal-title":"Oncoimmunology."},{"key":"B72","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/annonc\/mdr341","article-title":"A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma","volume":"23","author":"Chia","year":"2012","journal-title":"Ann Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1248\/cpb.c16-00114","article-title":"The Safety and Immunological Effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: a phase I clinical trial and two-year follow-up","volume":"64","author":"Si","year":"2016","journal-title":"Chem Pharm Bull (Tokyo)."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1126\/science.abm7930","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"375","author":"Robinson","year":"2022","journal-title":"Science."},{"key":"B77","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0961203314531637","article-title":"Viruses as potential pathogenic agents in systemic lupus erythematosus","volume":"23","author":"Nelson","year":"2014","journal-title":"Lupus."},{"key":"B78","doi-asserted-by":"publisher","first-page":"010405","DOI":"10.7189\/jogh.10.010405","article-title":"Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence","volume":"10","author":"Bakkalci","year":"2020","journal-title":"J Glob Health."},{"key":"B79","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3389\/fonc.2019.00104","article-title":"Progress in EBV Vaccines","volume":"9","author":"Van Zyl","year":"2019","journal-title":"Front Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1007\/s00018-020-03538-3","article-title":"Vaccination against the Epstein-Barr virus","volume":"77","author":"Ruhl","year":"2020","journal-title":"Cell Mol Life Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nrneurol.2010.1","article-title":"Environmental factors and their timing in adult-onset multiple sclerosis","volume":"6","author":"Handel","year":"2010","journal-title":"Nat Rev Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ana.21978","article-title":"Primary infection with the Epstein-Barr virus and risk of multiple sclerosis","volume":"67","author":"Levin","year":"2010","journal-title":"Ann Neurol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3389\/fneur.2019.01368","article-title":"High levels of Epstein-Barr virus nuclear antigen-1-specific antibodies and infectious mononucleosis act both independently and synergistically to increase multiple sclerosis risk","volume":"10","author":"Hedstrom","year":"2019","journal-title":"Front Neurol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/eji.202048655","article-title":"Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15","volume":"51","author":"Zdimerova","year":"2021","journal-title":"Eur J Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1016\/j.vaccine.2021.02.072","article-title":"Zero-dose children and the immunisation cascade: understanding immunisation pathways in low and middle-income countries","volume":"39","author":"Cata-Preta","year":"2021","journal-title":"Vaccine."},{"key":"B86","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1186\/s12889-020-09049-x","article-title":"Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom","volume":"20","author":"Kuri","year":"2020","journal-title":"BMC Public Health."},{"key":"B87","unstructured":"2021"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awl067","article-title":"Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis","volume":"129","author":"Lunemann","year":"2006","journal-title":"Brain."},{"key":"B89","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jneuroim.2014.04.005","article-title":"Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1","volume":"272","author":"Ruprecht","year":"2014","journal-title":"J Neuroimmunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/imm.12808","article-title":"Programmed death 1 is highly expressed on CD8(+) CD57(+) T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus","volume":"152","author":"Cencioni","year":"2017","journal-title":"Immunology."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1038\/cti.2016.87","article-title":"Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis","volume":"6","author":"Pender","year":"2017","journal-title":"Clin Transl Immunology."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e124714","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis","volume":"3","author":"Pender","year":"2018","journal-title":"JCI Insight."},{"key":"B93","doi-asserted-by":"publisher","first-page":"652811","DOI":"10.3389\/fneur.2021.652811","article-title":"Sustained clinical improvement in a subset of patients with progressive multiple sclerosis treated with epstein-barr virus-specific T cell therapy","volume":"12","author":"Ioannides","year":"2021","journal-title":"Front Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.887794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T06:51:32Z","timestamp":1656053492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.887794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":93,"alternative-id":["10.3389\/fneur.2022.887794"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.887794","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"article-number":"887794"}}